News

KYORIN Pharmaceutical Co., Ltd. announced today that it will commence promotion activities for Alesion® eyelid cream 0.5% (generic name: epinastine hydrochloride, hereinafter Alesion® Cream), along-acting treatment for allergic conjunctivitis, effective August 17, 2026.
This initiative is based on the joint marketing agreement in Japan for Alesion® Cream, which was executed on July 13, 2026 with Santen Pharmaceutical Co., Ltd. (Head Office: Osaka City, Osaka; hereinafter Santen). Under the agreement, Santen will continue to be responsible for manufacturing, product distribution, and detailing for medical institutions specializing in the field of ophthalmology, with KYORIN handling detailing for medical institutions outside this field.
The two partners--KYORIN, with expertise in allergic diseases and a strong sales and marketing platform in the respiratory and otolaryngology fields, and Santen, a company specialized in ophthalmology, expect this joint marketing to enable them to deliver Alesion® Cream, a new treatment option for allergic conjunctivitis, to as many patients as possible, thereby contributing to improved patient quality of life (QOL).